MARTIN KENNETH J 4
4 · Talecris Biotherapeutics Holdings Corp. · Filed Jun 3, 2011
Insider Transaction Report
Form 4
MARTIN KENNETH J
Director
Transactions
- Disposition to Issuer
Options (right to buy)
2011-06-01−12,616→ 0 totalExercise: $9.88From: 2009-04-01Exp: 2018-04-21→ Common Stock (12,616 underlying) - Disposition to Issuer
Options (right to buy)
2011-06-01−7,848→ 0 totalExercise: $16.63From: 2010-04-01Exp: 2019-03-27→ Common Stock (7,848 underlying) - Disposition to Issuer
Options (right to buy)
2011-06-01−6,256→ 0 totalExercise: $19.87From: 2011-04-01Exp: 2020-04-01→ Common Stock (6,256 underlying) - Disposition to Issuer
Common Stock
2011-06-01−12,715→ 0 total - Disposition to Issuer
Options (right to buy)
2011-06-01−8,576→ 0 totalExercise: $11.00From: 2008-04-01Exp: 2017-10-10→ Common Stock (8,576 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to the merger agreement between Issuer, Stream Merger Sub, Inc., Grifols, S.A., and Grifols, Inc. in exchange for $19.00 in cash and 0.6410 non-voting (Class B) ordinary shares of Grifols, S.A. (the Grifols B shares) (in the form of American Depository Shares (the Grifols ADS); with each Grifols ADS representing one-half of one Grifols B share) per Issuer share, with each Grifols ADS having a market value of $7.65 per Grifols ADS on the first trading day of the Grifols ADSs following the effective date of the merger.
- [F2]This option, which was fully vested and exercisable, deemed subject to a cashless exercise pursuant to the merger agreement, and the net number of Issuer shares deemed issued in connection with the deemed cashless exercise (after taking into account the exercise price of the option and applicable withholding taxes) were disposed of pursuant to the merger agreement in exchange for $19 in cash and 0.6410 Grifols ADSs per Issuer share deemed issued, with each Grifols ADS having a market value of $7.65 per Grifols ADS on the first trading day of the Grifols ADSs following the effective date of the merger.